Aleksander Krag

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6988176/publications.pdf

Version: 2024-02-01

		31976	36028
234	11,248	53	97
papers	citations	h-index	g-index

247	247	247	9072
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460.	3.7	1,762
2	Liver cirrhosis. Lancet, The, 2021, 398, 1359-1376.	13.7	515
3	Assessment of biopsyâ€proven liver fibrosis by twoâ€dimensional shear wave elastography: An individual patient dataâ€based metaâ€analysis. Hepatology, 2018, 67, 260-272.	7.3	322
4	Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut, 2010, 59, 105-110.	12.1	309
5	Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut, 2012, 61, 297-310.	12.1	303
6	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
7	Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology, 2010, 51, 576-584.	7.3	252
8	Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. American Journal of Physiology - Renal Physiology, 2015, 308, G807-G830.	3.4	200
9	Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. Gastroenterology, 2016, 150, 123-133.	1.3	186
10	The window hypothesis: haemodynamic and non-haemodynamic effects of Î²-blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1. Gut, 2012, 61, 967-969.	12.1	180
11	ADAPT: An Algorithm Incorporating PROâ€C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology, 2019, 69, 1075-1086.	7.3	174
12	Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology, 2018, 154, 1369-1379.	1.3	170
13	Systematic review with metaâ€analysis: the effects of rifaximin in hepatic encephalopathy. Alimentary Pharmacology and Therapeutics, 2014, 40, 123-132.	3.7	168
14	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
15	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	7.3	144
16	Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology and Hepatology, 2016, 1, 256-260.	8.1	131
17	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 185-198.	8.1	130
18	Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology, 2007, 46, 1863-1871.	7.3	126

#	Article	IF	Citations
19	Shearâ€wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. Liver International, 2017, 37, 396-405.	3.9	113
20	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	3.7	112
21	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1109-1116.	3.7	112
22	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	7.3	107
23	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology, 2019, 71, 1141-1151.	3.7	104
24	Nonselective Î²â€blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology, 2016, 63, 1968-1976.	7.3	100
25	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	3.7	97
26	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	1.3	97
27	Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 167-180.	17.8	97
28	Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. The Cochrane Library, 2012, , CD004544.	2.8	96
29	Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and metaâ€analysis. Liver International, 2015, 35, 2072-2078.	3.9	93
30	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 614-625.	8.1	91
31	Noninvasive proteomic biomarkers for alcohol-related liver disease. Nature Medicine, 2022, 28, 1277-1287.	30.7	91
32	Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Alimentary Pharmacology and Therapeutics, 2013, 38, 1086-1096.	3.7	85
33	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology, 2019, 157, 705-719.e18.	1.3	82
34	Terlipressin for hepatorenal syndrome. , 2012, , CD005162.		81
35	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clinical Gastroenterology and Hepatology, 2022, 20, 2567-2576.e6.	4.4	80
36	Metaâ€analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Alimentary Pharmacology and Therapeutics, 2012, 35, 1155-1165.	3.7	79

#	Article	IF	Citations
37	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	3.7	76
38	Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. Journal of Hepatology, 2018, 68, 1025-1032.	3.7	75
39	Metaâ€analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Alimentary Pharmacology and Therapeutics, 2012, 36, 619-626.	3.7	73
40	Review article: the efficacy of biomarkers in chronic fibroproliferative diseases â€“ early diagnosis and prognosis, with liver fibrosis as an exemplar. Alimentary Pharmacology and Therapeutics, 2014, 40, 233-249.	3.7	72
41	Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. Journal of Hepatology, 2021, 75, 1017-1025.	3.7	70
42	Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohnâ€™s Disease from Ulcerative Colitis. Journal of Crohn's and Colitis, 2015, 9, 863-872.	1.3	69
43	Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. American Journal of Physiology - Renal Physiology, 2016, 311, G1009-G1017.	3.4	69
44	Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 1085-1092.	1.6	68
45	Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2011, 23, 1218-1225.	1.6	68
46	The Effect of Anti-Tumor Necrosis Factor Alpha Agents on Postoperative Anastomotic Complications in Crohnâ€™s Disease. Diseases of the Colon and Rectum, 2013, 56, 1423-1433.	1.3	67
47	The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673.	7.3	67
48	Nonâ€selective betaâ€blockers may reduce risk of hepatocellular carcinoma: a metaâ€analysis of randomized trials. Liver International, 2015, 35, 2009-2016.	3.9	65
49	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ^—Z Variant of AAT (Piâ^—MZ vs) Tj ETQq1 1 0.784314 rgB	1.3	63
50	Transcriptional Dynamics of Hepatic Sinusoidâ€Associated Cells After Liver Injury. Hepatology, 2020, 72, 2119-2133.	7.3	62
51	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, doubleâ€blind, placeboâ€controlled trial. Hepatology, 2017, 65, 592-603.	7.3	60
52	The cardiorenal link in advanced cirrhosis. Medical Hypotheses, 2012, 79, 53-55.	1.5	59
53	Metaâ€analysis: isosorbideâ€mononitrate alone or with either betaâ€blockers or endoscopic therapy for the management of oesophageal varices. Alimentary Pharmacology and Therapeutics, 2010, 32, 859-871.	3.7	57
54	Systematic review and metaâ€analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatology Research, 2012, 42, 1008-1015.	3.4	55

#	Article	IF	Citations
55	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLoS ONE, 2015, 10, e0137302.	2.5	54
56	Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Advances in Therapy, 2008, 25, 1105-1140.	2.9	52
57	Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. Gut, 2016, 65, 1057-1058.	12.1	52
58	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 307-314.	2.8	51
59	Treatment of acute variceal bleeding. Digestive and Liver Disease, 2008, 40, 328-336.	0.9	50
60	Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. American Journal of Physiology - Renal Physiology, 2008, 295, F1295-F1300.	2.7	46
61	Cardiac dysfunction in cirrhosis â€“ does adrenal function play a role? A hypothesis. Liver International, 2012, 32, 1327-1332.	3.9	46
62	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatology Communications, 2018, 2, 211-222.	4.3	45
63	High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. PLoS ONE, 2017, 12, e0173992.	2.5	44
64	High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 619-626.	1.6	43
65	Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. Scandinavian Journal of Gastroenterology, 2015, 50, 584-592.	1.5	43
66	The heart and the liver. Expert Review of Gastroenterology and Hepatology, 2009, 3, 51-64.	3.0	42
67	Acute kidney injury and hepatorenal syndrome in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 236-243.	2.8	42
68	Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. Ultraschall in Der Medizin, 2017, 38, 648-654.	1.5	42
69	Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver International, 2014, 34, 1153-1163.	3.9	40
70	Ulcerative colitis, Crohnâ€™s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohnâ€™s disease. PLoS ONE, 2017, 12, e0185855.	2.5	40
71	Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Frontiers in Physiology, 2013, 4, 195.	2.8	39
72	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	12.1	39

#	Article	IF	Citations
73	Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis. Clinical Gastroenterology and Hepatology, 2022, 20, 1784-1794.e9.	4.4	38
74	Large Variations in Risk of Hepatocellular Carcinoma and Mortality in Treatment NaÃ¯ve Hepatitis B Patients: Systematic Review with Meta-Analyses. PLoS ONE, 2014, 9, e107177.	2.5	37
75	Combination of CCl₄ with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, G182-G194.	3.4	37
76	Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver International, 2009, 29, 1528-1537.	3.9	35
77	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
78	Terlipressin versus other vasoactive drugs for hepatorenal syndrome. The Cochrane Library, 2017, 2017, CD011532.	2.8	34
79	Costâ€Effectiveness of Noninvasive Screening for Alcoholâ€Related Liver Fibrosis. Hepatology, 2020, 71, 2093-2104.	7.3	34
80	Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Journal of Hepatology, 2021, 75, 810-819.	3.7	34
81	Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension. PLoS ONE, 2013, 8, e83341.	2.5	34
82	Individualized care for portal hypertension: Not quite yet. Journal of Hepatology, 2015, 63, 543-545.	3.7	32
83	Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. The Cochrane Library, 2017, 2017, CD005162.	2.8	32
84	The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5. Liver International, 2010, 30, 455-462.	3.9	31
85	Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers matters. Journal of Hepatology, 2016, 64, 1455-1456.	3.7	31
86	Spleen stiffness to liver stiffness ratio significantly differs between ALD and HCV and predicts disease-specific complications. JHEP Reports, 2019, 1, 99-106.	4.9	31
87	Targeting the Gutâ€“Liver Axis in Cirrhosis: Antibiotics and Non-Selective Î²-Blockers. Advances in Therapy, 2013, 30, 659-670.	2.9	30
88	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open, 2013, 3, e003265.	1.9	30
89	Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2012, 2, e001313.	1.9	29
90	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE, 2014, 9, e108544.	2.5	29

#	Article	IF	Citations
91	Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Alimentary Pharmacology and Therapeutics, 2016, 44, 1242-1252.	3.7	29
92	Nutrition impact symptoms, handgrip strength and nutritional risk in hospitalized patients with gastroenterological and liver diseases. Scandinavian Journal of Gastroenterology, 2015, 50, 1191-1198.	1.5	28
93	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	12.1	28
94	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	3.7	28
95	Assessment of response to beta-blockers by expression of Î²Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. Journal of Hepatology, 2016, 64, 1265-1273.	3.7	27
96	Collagen proportionate area predicts clinical outcomes in patients with alcoholâ€related liver disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1728-1739.	3.7	27
97	Collagen type IV remodelling genderâ€specifically predicts mortality in decompensated cirrhosis. Liver International, 2019, 39, 885-893.	3.9	26
98	Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?. Hepatology, 2020, 71, 346-351.	7.3	26
99	Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis. Digestive Diseases and Sciences, 2019, 64, 3134-3142.	2.3	25
100	Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. Aids, 2014, 28, 2081-2090.	2.2	24
101	Pathophysiological aspects of pulmonary complications of cirrhosis. Scandinavian Journal of Gastroenterology, 2007, 42, 419-427.	1.5	23
102	Betablockers induce cardiac chronotropic incompetence. Journal of Hepatology, 2012, 56, 298-299.	3.7	23
103	Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients. Scandinavian Journal of Gastroenterology, 2016, 51, 1354-1359.	1.5	23
104	A Dynamic Aspartateâ€toâ€Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatology Communications, 2021, 5, 1021-1035.	4.3	23
105	Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scandinavian Journal of Gastroenterology, 2014, 49, 362-372.	1.5	22
106	Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients. Scientific Reports, 2019, 9, 14857.	3.3	22
107	Progressive alcoholâ€related liver fibrosis is characterised by imbalanced collagen formation and degradation. Alimentary Pharmacology and Therapeutics, 2021, 54, 1070-1080.	3.7	22
108	Serum Neutrophil Gelatinase-Associated Lipocalin â€“ A Sensitive Novel Marker of Renal Impairment in Liver Cirrhosis?. Digestion, 2011, 84, 82-83.	2.3	21

#	Article	IF	Citations
109	Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?. Medical Hypotheses, 2013, 81, 871-874.	1.5	21
110	Effect of paracentesis on metabolic activity in patients with advanced cirrhosis and ascites. Scandinavian Journal of Gastroenterology, 2016, 51, 601-609.	1.5	21
111	Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Reports, 2021, 3, 100325.	4.9	20
112	Effects of a 6â€month, lowâ€carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An openâ€label randomized controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 693-703.	4.4	20
113	Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillarâ€associated protein 4. Liver International, 2020, 40, 1701-1712.	3.9	19
114	PROâ€C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcoholâ€related liver disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 699-708.	3.7	19
115	Cutaneous Porphyrias: Causes, Symptoms, Treatments and the Danish Incidence 1989â€“2013. Acta Dermato-Venereologica, 2016, 96, 868-872.	1.3	18
116	Serum type <scp>XVI</scp> collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders. Cancer Medicine, 2018, 7, 4619-4626.	2.8	18
117	Contemporary use of elastography in liver fibrosis and portal hypertension. Clinical Physiology and Functional Imaging, 2017, 37, 235-242.	1.2	17
118	Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology, 2023, 77, 558-572.	7.3	17
119	Cameron lesions: an often overlooked cause of iron deficiency anaemia in patients with large hiatal hernias. BMJ Case Reports, 2010, 2010, bcr0620103129-bcr0620103129.	0.5	16
120	Profermin is Efficacious in Patients with Active Ulcerative Colitisâ€"A Randomized Controlled Trial. Inflammatory Bowel Diseases, 2013, 19, 2584-2592.	1.9	16
121	Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Preference and Adherence, 2014, 8, 331.	1.8	16
122	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. Journal of Hepatology, 2021, 74, 200-219.	3.7	16
123	Hyponatraemia during terlipressin therapy. Gut, 2010, 59, 417-418.	12.1	15
124	Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS. Digestive Diseases and Sciences, 2015, 60, 3456-3464.	2.3	15
125	Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C. PLoS ONE, 2019, 14, e0212036.	2.5	15
126	Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study. PLoS ONE, 2014, 9, e109179.	2.5	15

#	Article	IF	Citations
127	Safety and efficacy of ProferminÂ®to induce remission in ulcerative colitis. World Journal of Gastroenterology, 2012, 18, 1773.	3.3	15
128	Characteristics of randomised trials on diseases in the digestive system registered in ClinicalTrials.gov: a retrospective analysis. BMJ Open, 2011, 1, e000309-e000309.	1.9	14
129	Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care. Scientific Reports, 2022, 12, 2914.	3.3	14
130	Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease. Gut, 2017, 66, 558-559.	12.1	13
131	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). The Cochrane Library, 2017, 2017, CD011646.	2.8	13
132	Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials, 2018, 19, 143.	1.6	13
133	Serological Assessment of the Quality of Wound Healing Processes in Crohnâ€™s Disease. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 175-182.	0.9	13
134	Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice. World Journal of Gastroenterology, 2015, 21, 8964.	3.3	13
135	Impaired free water excretion in child C cirrhosis and ascites: relations to distal tubular function and the vasopressin system. Liver International, 2010, 30, 1364-1370.	3.9	12
136	Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites?. Hepatology, 2011, 53, 370-371.	7.3	12
137	Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PROâ€€3). Liver International, 2022, 42, 92-101.	3.9	12
138	Research report: do general practitioners tell their patients about side effects to common treatments?. Social Science and Medicine, 2004, 59, 1677-1683.	3.8	11
139	Adherence to guidelines in bleeding oesophageal varices and effects on outcome: comparison between a specialized unit and a community hospital. European Journal of Gastroenterology and Hepatology, 2010, 22, 1221-1227.	1.6	11
140	Alcoholic liver disease: A registry view on comorbidities and disease prediction. PLoS Computational Biology, 2020, 16, e1008244.	3.2	11
141	Cardiorenal Syndrome â€“ A New Entity?. Frontiers of Gastrointestinal Research, 2010, , 102-111.	0.1	10
142	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. Liver International, 2015, 35, 1393-1402.	3.9	10
143	Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. American Journal of Physiology - Renal Physiology, 2020, 318, G313-G321.	3.4	10
144	Describing the fecal metabolome in cryogenically collected samples from healthy participants. Scientific Reports, 2020, 10, 885.	3.3	10

#	Article	IF	Citations
145	Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD. Scientific Reports, 2021, 11, 14713.	3.3	10
146	The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary. Gastroenterology, 2022, 162, 1561-1567.	1.3	10
147	O018 : 2D-shear wave elastography is equivalent or superior to transient elastography for liver fibrosis assessment: Results from an individual patient data based meta-analysis. Journal of Hepatology, 2015, 62, S199-S200.	3.7	9
148	Diagnostic accuracy of routine liver function tests to identify patients with significant and advanced alcohol-related liver fibrosis. Scandinavian Journal of Gastroenterology, 2021, 56, 1088-1095.	1.5	9
149	Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. Pathology Research and Practice, 2022, 231, 153798.	2.3	9
150	Prescribing of acid suppressive therapy: interactions between hospital and primary care. Alimentary Pharmacology and Therapeutics, 2006, 23, 1713-1718.	3.7	8
151	Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2010, 105, 1444.	0.4	8
152	Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. American Journal of Physiology - Renal Physiology, 2010, 299, G784-G790.	3.4	8
153	To block, or not to block in advanced cirrhosis and ascites: that is the question. Gut, 2015, 64, 1015-1017.	12.1	8
154	Lack of consensus for usage of Î²-blockers in end-stage liver disease. Gut, 2016, 65, 1058-1060.	12.1	8
155	Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?. Journal of Hepatology, 2018, 69, 769-771.	3.7	8
156	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. Liver Transplantation, 2020, 26, 1652-1657.	2.4	8
157	168 REDUCED MORTALITY WITH NON-SELECTIVE BETABLOCKERS COMPARED TO BANDING IS NOT RELATED TO PREVENTION OF BLEEDING OR BLEEDING RELATED MORTALITY: SYSTEMATIC REVIEW OF RANDOMIZED TRIALS. Journal of Hepatology, 2011, 54, S72.	3.7	7
158	Hyponatremia in patients treated with terlipressin: Mechanisms and implications for clinical practice. Hepatology, 2011, 53, 368-369.	7.3	7
159	O073 : Non-selective beta-blockers and mortality in cirrhosis patients with or without refractory ascites: Post hoc analysis of three large RCTâ€™s with 1198 patients. Journal of Hepatology, 2015, 62, S227.	3.7	7
160	Cross-talk between the Liver, Heart and Kidney â€“ another Piece in the Puzzle. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 119-121.	0.9	7
161	Effects of a single dose of terlipressin on transcutaneous oxygen pressures. Scandinavian Journal of Gastroenterology, 2010, 45, 953-958.	1.5	6
162	Alcoholic Cirrhosis Increases Risk for Autoimmune Diseases: A Nationwide Registry-Based Cohort Study. Clinical Gastroenterology and Hepatology, 2015, 13, 2017-2022.	4.4	6

#	Article	IF	Citations
163	Internal dysregulation of the renin system in patients with stable liver cirrhosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 298-309.	1.2	6
164	The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary. Journal of Hepatology, 2022, 76, 995-1000.	3.7	6
165	[234] CARDIAC EFFECTS OF TERLIPRESSIN IN CIRRHOSI S. UNMASKING A CIRRHOTIC CARDIOMYOPATHY?. Journal of Hepatology, 2007, 46, S96.	3.7	5
166	Safety of Terlipressin for Hepatorenal Syndrome. Frontiers of Gastrointestinal Research, 2011, , 178-188.	0.1	5
167	Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 112-116.	1.2	5
168	Rifaximin for people with hepatic encephalopathy. The Cochrane Library, 0, , .	2.8	5
169	Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patientsâ€™ Experience on Rifaximin-Î± (PROSPER): an observational study among 550 patients. Hepatology, Medicine and Policy, 2018, 3, 4.	1.7	5
170	High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health. Metabolites, 2022, 12, 211.	2.9	5
171	Hepatorenal Index by Bâ€Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcoholâ€Related and Nonalcoholic Fatty Liver Disease. Journal of Ultrasound in Medicine, 2022, , .	1.7	5
172	Effects of treatment with Î²-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis. European Journal of Gastroenterology and Hepatology, 2011, 23, 334-342.	1.6	4
173	Is liver stiffness equal to liver fibrosis?. Hepatology, 2017, 65, 749-749.	7.3	4
174	Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. Scientific Reports, 2020, 10, 9537.	3.3	4
175	A Serological Biomarker of Laminin Gamma 1 Chain Degradation Reflects Altered Basement Membrane Remodeling in Crohnâ€™s Disease and DSS Colitis. Digestive Diseases and Sciences, 2022, 67, 3662-3671.	2.3	4
176	External validation of a genetic risk score that predicts development of alcohol-related cirrhosis. Journal of Hepatology, 2022, 77, 1720-1721.	3.7	4
177	Effect of meal and propranolol on whole body and splanchnic oxygen consumption in patients with cirrhosis. American Journal of Physiology - Renal Physiology, 2006, 291, G8-G15.	3.4	3
178	Endoscopic treatment of bleeding esophageal varices. Endoscopy, 2007, 39, 373-373.	1.8	3
179	295 LOW CARDIAC INDEX PREDICTS SURVIVAL AND RENAL FAILURE IN PATIENTS WITH ASCITES. EVIDENCE OF A HEART-KIDNEY AXIS IN CIRRHOSIS. Journal of Hepatology, 2008, 48, S118.	3.7	3
180	Terlipressin vs. Octreotide in Bleeding Esophageal Varices. American Journal of Gastroenterology, 2009, 104, 2351-2351.	0.4	3

#	Article	IF	Citations
181	Aquaporinâ€2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1087-1093.	2.8	3
182	Managing excessive alcohol consumption at a population level: The earlier the better. Journal of Hepatology, 2018, 68, 389-390.	3.7	3
183	Extracellular Matrix Remodeling with Focus on Biochemical Markers in Liver Fibrosis: Limitations and Possibilities. , 2019, , 265-286.		3
184	Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis. American Journal of Physiology - Renal Physiology, 2020, 318, G410-G418.	3.4	3
185	Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Biomarkers in Disease, 2017, , 221-246.	0.1	3
186	How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership. BMJ Open, 2022, 12, e058179.	1.9	3
187	Terlipressin and hyponatraemia: the cause or the treatment?. Internal Medicine Journal, 2013, 43, 606-607.	0.8	2
188	Variceal Rebleeding: Drugs, Endoscopy or Both. , 2014, , 213-228.		2
189	Prediction of presence of oesophageal varices just by shearâ€wave elastography of the liver and spleen. Liver International, 2017, 37, 1406-1407.	3.9	2
190	2D Shear Wave Elastography Predicts Survival in Advanced Chronic Liver Disease: AIXPLORER PREDICT and VALIDATE. , 2021, 59, .		2
191	Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Reports, 2021, 3, 100287.	4.9	2
192	A rare cause of severe hepatomegaly with an improving outcome. BMJ Case Reports, 2014, 2014, bcr2013203360-bcr2013203360.	0.5	2
193	Diagnostic challenges in patients with alcohol-related liver disease. Zeitschrift Fur Gastroenterologie, 2022, 60, 45-57.	0.5	2
194	Endoscopic variceal ligation alone or with pharmacological therapy for recurrent variceal bleeding: the importance of intentionâ€toâ€treat analyses. Alimentary Pharmacology and Therapeutics, 2010, 31, 341-343.	3.7	1
195	Letter: the effects of rifaximin in hepatic encephalopathy - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 858-859.	3.7	1
196	P0524 : Impact of number of measurements on diagnostic performance of real time shear-wave elastography: A biopsy-controlled study. Journal of Hepatology, 2015, 62, S511-S512.	3.7	1
197	Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices. The Cochrane Library, 0, , .	2.8	1
198	How to achieve a smooth transition from fellowship to faculty. United European Gastroenterology Journal, 2016, 4, 717-718.	3.8	1

#	Article	IF	Citations
199	Editorial: in vino veritas â€“ transient elastography for staging liver fibrosis in alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1014-1015.	3.7	1
200	Editorial: the portal hypertension puzzleâ€”spleen stiffness evades validation as nonâ€invasive marker of clinically significant portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 47, 856-857.	3.7	1
201	P125 Basement membrane remodelling as a biomarker for monitoring disease activity in Crohnâ€™s disease patients: the role of laminin. Journal of Crohn's and Colitis, 2018, 12, S155-S156.	1.3	1
202	Time to Reconsider Listing Criteria for Alcoholâ€Associated Liver Disease?. Liver Transplantation, 2019, 25, 1303-1304.	2.4	1
203	P301 A serological biomarker of type VIII collagen that contains the anti-angiogenic signalling molecule, vastatin, is associated with the extension of disease in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S250-S251.	1.3	1
204	P235 Serological biomarkers of interstitial matrix and basement membrane remodelling correlate the Modified Mayo Endoscopic Score (mMES) for ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S260-S261.	1.3	1
205	2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. Insights Into Imaging, 2021, 12, 145.	3.4	1
206	Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyond. Journal of Hepatology, 2022, 77, 278-281.	3.7	1
207	Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis: authors' reply. Liver International, 2011, 31, 139-140.	3.9	0
208	Letter: vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 1104-1104.	3.7	0
209	Sa1230 Specific Fragments of Extracellular Matrix Proteins Reflect Disease Activity in Ulcerative Colitis. Gastroenterology, 2014, 146, S-237.	1.3	0
210	Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices. The Cochrane Library, 0, , .	2.8	0
211	Reply. Hepatology, 2016, 64, 1808-1808.	7.3	0
212	Reply. Gastroenterology, 2016, 150, 1252-1253.	1.3	0
213	Screening studies of transient elastography and FibroTest in the general population â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 246-247.	8.1	0
214	P217 Serological biomarkers of type VI collagen remodelling reflect endoscopically and clinically active Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S203-S205.	1.3	0
215	P357 Serological biomarkers of interstitial matrix and basement membrane remodelling correlate to disease activity in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S282-S283.	1.3	0
216	P637 MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2019, 13, S436-S437.	1.3	0

#	Article	IF	Citations
217	Clinical Aspects of Alcoholic Liver Disease. , 2019, , 3-21.		0
218	2D shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
219	Effects of Ethanol Feeding in Early-Stage NAFLD Mice Induced by Western Diet. Livers, 2021, 1, 27-39.	1.9	0
220	P165 Non-invasive biomarkers of type III collagen cross-linking reflects fibrolysis in patient with luminal CROHNâ€™S DISEASE. Journal of Crohn's and Colitis, 2021, 15, S241-S242.	1.3	0
221	Einfluss der Augmentationstherapie mit Alpha1-Antitrypsin auf den LeberphÃnotyp von Individuen mit klassischem Alpha1-Antitrypsin-Mangel (Genotyp Pi*ZZ). Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
222	Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Exposure and Health, 2015, , 1-26.	4.9	0
223	Consensus Statements: Changing Scenarios: Prevention of Decompensation. , 2016, , 235-238.		0
224	Introduction: Prevention of Decompensation Versus Prevention of First Bleeding. , 2016, , 195-204.		0
225	Result of the Questionnaire. , 2016, , 187-194.		0
226	Controlled attenuation parameter predicts steatosis in alcoholic liver disease and correlates with poor metabolic phenotype and cardiovascular risk: A biopsy-controlled multicenter study. , 2017, 55, .		0
227	Serological assessment of type Î§VÎ™ collagen in patients with colorectal cancer and ulcerative colitis.. Journal of Clinical Oncology, 2018, 36, 698-698.	1.6	0
228	Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease-specific complications. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
229	Die Substitution mit Alpha1-Antitrypsin ist bei Patienten mit schwerem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit einer Verbesserung Leber-bezogener Parameter assoziiert. , 2019, 57, .		0
230	EuropÃische Studie: Heterozygoter Alpha-1-Antitrypsinmangel (Pi*MZ) fÃ¼hrt zu einem intermediÃren Leber-PhÃnotyp. , 2020, 58, .		0
231	Die Augmentation mit Alpha1-Antitrypsin assoziiert bei Patienten mit klassischem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit besseren Leber-Parametern. , 2020, 58, .		0
232	Die Therapie mit Alpha-1-Antitrypsin (AAT) assoziiert bei AAT-Mangel mit besseren Leber-bezogenen Parametern. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.5	0
233	Editorial: biomarkers for alcoholâ€related liver fibrosisâ€”almost there? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1494-1495.	3.7	0
234	Reply. When to stop non-selective beta-blockers: the window hypothesis in clinical practice. Journal of Gastrointestinal and Liver Diseases, 2014, 23, 458.	0.9	0